Challenges of general safety evaluations of biologics compared to small molecule pharmaceuticals in animal models

Bibliography

• Olson H, Betton G, Robinson D, Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 2000;32:56-67
   PubMed Web of Science ®Google Scholar
• Rituximab BLA. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm
   Google Scholar
• ICH S6, Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals, July 1997 Available from: http://www.ich.org
   Google Scholar
• US Food and Drug Administration Center for Biologics Evaluation and Research, “Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use”, Feb 28, 1997
   Google Scholar
• Bussiere JL, Martin P, Horner M, Alternative strategies for toxicity testing of species-specific biopharmaceuticals. Int J Toxicol 2009;28(3):230-53
   PubMed Web of Science ®Google Scholar
• Ferrara C, Stuart F, Sondermann P, The Carbohydrate at FcgammaRIIIa Asn-162: an element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem 2006;281(8):5032-6
   PubMed Web of Science ®Google Scholar
• Dall’Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 2006;281:23514-24
   PubMed Web of Science ®Google Scholar
• Krolick KA, Villemez C, Isakson P, Selective killing of normal or neoplastic B cells by antibodies coupled to the A chain of ricin. Proc Natl Acad Sci USA 1980;77:5419-23
   PubMed Web of Science ®Google Scholar
• Pastan I, FitzGerald D. Pseudomonas exotoxin: chimeric toxins. J Biol Chem 1989;264:15157-60
   PubMed Web of Science ®Google Scholar
• Pastan I. Immunotoxins containing pseudomonas exotoxin A: a short history. Cancer Immunol Immunother 2003;52:338-41
   PubMed Web of Science ®Google Scholar
• Herschman HR, Simpson DL, Cawley DB. Toxic ligand conjugates as tools in the study of receptor-ligand interactions. J Cell Biochem 1982;20:163-76
   PubMed Web of Science ®Google Scholar
• Brown JG, Entwistle J, Glover N, Macdonald GC. Preclinical safety evaluation of immunotoxins. In: J Cavagnaro, editor, Preclinical safety evaluation of biopharmaceuticals: a science-based approach to facilitating clinical trials, John Wiley & Sons, Hoboken, NJ; 2008. p. 649-67
   Google Scholar
• Kreitman RJ. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. BioDrugs 2009;23(1):1-13
   PubMed Web of Science ®Google Scholar
• Hwang J, FitzGerald DJ, Adhya S, Pastan I. Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. Coli. Cell 1987;48:129-36
   PubMed Web of Science ®Google Scholar
• Kondo K, FitzGerald DJ, Chaudhary V. Activity of immunotoxins constructed with modified Pseudomonas exotoxin a lacking the cell recognition domain. J Biol Chem 1988;263(19):9470-5
   PubMed Web of Science ®Google Scholar
• Jinno Y, Chaudhary VK, Kondo T, Mutational analysis of domain I of Pseudomonas Exotoxin. Mutations in domain I of Pseudomonas exotoxin which reduce cell binding and animal toxicity. J Biol Chem 1988;263(26):13203-7
   PubMed Web of Science ®Google Scholar
• Siegall CB, Chaudhary V, FitzGerald DJ, Pastan I. Functional analysis of domains II, Ib and III of pseudomonas exotoxin. J Biol Chem 1989;264:14256-61
   PubMed Web of Science ®Google Scholar
• Onda M, Nagata S, FitzGerald DJ, Characterization of the B cell epitopes associated with a truncated form of Pseudomonas Exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J Immunol 2006;177:8822-34
   PubMed Web of Science ®Google Scholar
• Frankel AE, Kreitman RJ, Sausville EA. Targeted toxins. Clin Cancer Res 2000;6:334
   Web of Science ®Google Scholar
• Siegall CB, Liggitt D. Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity. Proc Natl Acad Sci USA 1994;91:9514-18
   PubMed Web of Science ®Google Scholar
• ICH M3 (R1), Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals, November 2000 Available from: http://www.ich.org. ICH M3 (R2), Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals, July 2008. Available from: http://www.ich.org
   Google Scholar
• Grimm D, Kay MA. Therapeutic application of RNAi: is mRNA targeting finally ready for prime time? J Clin Invest 2007;117(12):3633-41
   PubMed Web of Science ®Google Scholar
• Aigner A. Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo. Appl Microbiol Biotechnol 2007;76:9-21
   PubMed Web of Science ®Google Scholar
• Dykxhoorn DM, Lieberman J. Knocking down disease with siRNAs. Cell 2006;126:231-35
   PubMed Web of Science ®Google Scholar
• Burley SK, Park F. Meeting the challenges of drug discovery: a multidisciplinary re-evaluation of current practices. Genome Biol 2005;6:330.1-330.3
   Web of Science ®Google Scholar
• Barik S, Bitko V. Prospects of RNA interference therapy in respiratory viral diseases: update 2006. Expert Opin Biol Ther 2006;6(11):1151-60
   PubMed Web of Science ®Google Scholar
• Bitko V, Musiyenko A, Shulyayeva O, Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005;11(1):50-5
   PubMed Web of Science ®Google Scholar
• Morrissey DV, Lockridge JA, Shaw L, Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotech 2005;23(8):1002-7
   PubMed Web of Science ®Google Scholar
• Zender L, Kubicka S. SiRNA based strategies for inhibition of apoptotic pathways in vivo-analytical and therapeutic implications. Apoptosis 2004;9:51-4
   PubMed Web of Science ®Google Scholar
• Jansen B, Wacheck V, Heere-Ress E, Chemosensitization of malignant melanoma by BCL2 antisense therapy. Lancet 2000;356:1728-33
   PubMed Web of Science ®Google Scholar
• Athyros VG, Kakafika AI, Tziomalos K, Antisense technology for the prevention or the treatment of cardiovascular disease: the next blockbuster? Expert Opin Invest Drugs 2008:17(7):969-72
   PubMed Web of Science ®Google Scholar
• Levin AA, Henry SP. Toxicology of oligonucleotide therapeutics and understanding the relevance of the toxicities. In: J Cavagnaro, editor, Preclinical safety evalution of biopharmaceuticals: a science-based approach to facilitating clinical trials, John Wiley & Sons, Hoboken, NJ; 2008. p. 537-74
   Google Scholar
• Black LE, Farrelly JG, Cavagnaro JA, Regulatory considerations of oligonucleotide drugs: updated recommendations for pharmacology and toxicology studies. Antisense Res Dev 1994;4:299-301
   PubMedGoogle Scholar
• Black LE, DeGeorge JJ, Cavagnaro JA, Regulatory considerations for evaluating the pharmacology and toxicology of antisense drugs. Antisense Res Dev 1993;3:399-404
   PubMedGoogle Scholar
• Jackson AL, Burchard J, Schelter J, Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarity. RNA 2006;12:1179-87
   PubMed Web of Science ®Google Scholar
• Verdel A, Jia S, Gerber S, RNAI-mediated targeting of heterchrome by the RITS complex. Science 2004;303(5658):672-6
   PubMed Web of Science ®Google Scholar
• Henry SP, Novotny W, Leeds J, Inhibition of coagulation by a phosphorothioate oligonucleotide. Antisense Nucl Acid Drug Dev 1997;7:503-10
   PubMedGoogle Scholar
• Sheehan JP, Lan H-C. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex. Blood 1998;92(5):1617-25
   PubMed Web of Science ®Google Scholar
• Sheehan JP, Thao PM. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex by an allosteric mechanism. Biochemistry 2001;40(16):4980-9
   PubMed Web of Science ®Google Scholar
• Henry SP, Giclas PC, Leeds J, Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. J Pharmacol Exp Ther 1997;281(2):810-16
   PubMed Web of Science ®Google Scholar
• Henry SP, Beattie G, Yeh G, Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide. Int J Immunopharmacol 2002;2(12):1657-66
   PubMed Web of Science ®Google Scholar
• Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 2004;4(4):249-8
   PubMed Web of Science ®Google Scholar
• FDA G95-1 guidance. Available from: http://www.fda.gov/cdrh/g951.html
   Google Scholar
• US FDA CBER Guidance for Human Somatic Cell Therapy and Gene Therapy. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/ucm081670.pdf
   Google Scholar
• ICH S9, Nonclinical Evaluation for Anticancer Pharmaceuticals, Step 3, December 2008,US Food and Drug Administration Center for Biologics Evaluation and Research, Guidance for Industry, Considerations for plasmid DNA Vaccines for Infectious Disease Indications, November 2007 Available from: http://www.ich.org
   Google Scholar
• USA FDA Nonclinical Safety Evaluation of Pediatric Drug Products guidance. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079247.pdf
   Google Scholar
• EMEA. CHNP SWP Reflection Paper on the Assessment of the Genotoxic Potential of Antisense Oligodeoxynucleotides. EMEA/CHNP/SWP199726/2004 (2005). Available from: www.emea.europa.eu/pdfs/human/swp/19972604en.pdf
   Google Scholar
• Sutkowski EM, Gruber MF. Non-clinical Safety evaluation of preventive vaccines–regulatory considerations, business briefing. Future Drug Discov 3rd edition, June 2003;34-37
   Google Scholar
• Ball R. Methods of ensuring vaccine safety. Expert Rev Vaccines 2002;1(2):161-8
   PubMedGoogle Scholar
• World Health Organization Guidelines on Nonclinical Evaluation of Vaccines, WHO Expert Committee on Biological Standardization, November, 2003
   Google Scholar
• European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products, Points to Consider on the Development of Live attenuated Influenza Vaccines, February 20, 2003
   Google Scholar
• US Food and Drug Administration Center for Biologics Evaluation and Research and the Society of Toxicology Workshop on Nonclinical Safety Evaluation of Preventive Vaccines, Recent Advances and Regulatory Considerations, transcript, December 2, 2002 Available from: http://www.fda.gov/cber/minutes/tox120202.htm
   Google Scholar
• Dudas RA, Karron RA. Respiratory syncytial virus vaccines. Clin Microbiol Rev 1998;11(3):430-9
   PubMed Web of Science ®Google Scholar
• Sela M, Hilleman MR. Therapeutic vaccines: realities of today and hopes for tomorrow. PNAS 2004;101:14559
   PubMed Web of Science ®Google Scholar
• Koppele JT, Witkamp R. Use of animal models of disease in the preclinical safety evaluation of biopharmaceuticals. In: J Cavagnaro, editor, Preclinical safety evalution of biopharmaceuticals: a science-based approach to facilitating clinical trials, John Wiley & Sons, Hoboken, NJ; 2008. p. 293-308
   Google Scholar
• Dixit R, Boelsterli UA. Healthy animals and animal models of human disease(s) in safety assessment of human pharmaceuticals, including therapeutic antibodies. Drug Discov Today 2007;12(7/8):336-42
   PubMed Web of Science ®Google Scholar
• Cavagnaro JA. Preclinical safety evaluation of biotechnology-derived pharmaceuticals. Nat Drug Discov 2002; 1:469-75
   PubMed Web of Science ®Google Scholar
• Sims J. Assessment of biotechnology products for therapeutic use. Toxicol Lett 2001;120:59-66
   PubMed Web of Science ®Google Scholar
• Dempster M. Designing non-clinical safety evaluation programmes: the view of the toxicologist. In: Briffith SA, Lumley CE, editors, Safety evaluation of biotechnology-derived pharmaceuticals: facilitating a scientific approach. Kluwer academic, Lancaster; 1998. p. 7-15
   Google Scholar
• Arp LH. Tumor models: assessing toxicity in efficacy studies. Toxicol Pathol 1999;27:121-22
   PubMed Web of Science ®Google Scholar
• Yamada K, Nabeshima T. Animal models of Alzheimer's disease and evaluation of anti-dementia drugs. Pharmacol Ther 2000;88:93-113
   PubMed Web of Science ®Google Scholar
• Zak O, O’Reilly T. Animal models in the evaluation of antimicrobial agents. Antimicrob Agents Chemother 1991;35(8):1527-31
   PubMed Web of Science ®Google Scholar
• Bugelski PJ, Herzyk DJ, Rehm S, Preclinical development of keliximab, a Primatized® anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies. Hum Exp Toxicol 2000;19:230-43
   PubMed Web of Science ®Google Scholar
• Herzyk DJ, Gore ER, Polsky R, Immunomodulatory effects of anti-CD4 antibody in host resistance against infections and tumors in human CD4 transgenic mice. Infect Immunity 2001;69:1032-43
   PubMed Web of Science ®Google Scholar
• Killeen N, Sawada S, Littman DR. Regulated expression of human CD4 rescues helper T cell development in mice lacking expression of endogenous CD4. EMBO J 1993;12(4):1547-53
   PubMed Web of Science ®Google Scholar
• McLaughlin PM, Kroesen BJ, Dokter WH, An EGP-2/Ep-CAM-expressing transgenic rat model to evaluate antibody-mediated immunotherapy. Cancer Immunol Immunother 1999;48:303-411
   PubMed Web of Science ®Google Scholar
• Wells MY, Williams ES. The transgenic mouse assay as an alternative test method for regulatory carcinogenicity studies–implications for REACH. Regul Toxicol Pharmacol 2009;53:150-55
   PubMed Web of Science ®Google Scholar
• Bugelski PJ, Herzyk DJ, Rehm S, Preclinical development of keliximab, a primatized anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies. Human Exp Toxicol 2000;19(4):230-43
   PubMed Web of Science ®Google Scholar